What Happened?
Menlo Park, CA-based AccuraGen Holdings Appointed Shengrong Lin as President and Chief Technology Officer
About the Company
We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
About the Person
Shengrong Lin is President and Chief Technology Officer at AccuraGen Holdings. Previously, Shengrong held various senior HR leadership roles in the industry.
Info Source
News
Short Profile